Conditions: Alcoholic Hepatitis
Keywords: alcoholic hepatitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 5
Healthy volunteers: no

Brief summary:
The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.

Detailed description:
The study will also see if overall patient survival is affected at 6 months, and if the study drug improves liver function.

Arms:
arm 1: IDN-6556 capsules, 25 mg BID arm 2: Placebo capsules BID

Interventions: intervention 1: IDN-6556 intervention 2: Placebo
Intervention descriptions: intervention 1: 25 mg BID for 28 days intervention 2: Placebo controlled

Protocol document: